跳至主要内容
临床试验/NL-OMON30049
NL-OMON30049已完成4 期

Healing IIB Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth - HEALING IIb

genae associates0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
32

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • -Treatment of 1 or 2 de novo lesions;
  • -Target lesion(s) is(are) located in a native coronary artery, which can be covered by one single stent of maximum 33 mm;
  • - Reference vessel diameter min.2.5 and max.3.75 mm by visual estimate;
  • - Target lesion stenosis is >50% and <100%;
  • - The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent.

排除标准

  • - A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit;
  • - Documented or suspected liver disease;
  • - Recipient of heart transplant;
  • - Known allergies to aspirin, clopidogrel bisulphate and ticlopidine, heparin, or stainless steel;
  • - Any patient who previously received murine therapeutic antibodies and exhibited sensitization through the production of Human Anti-mouse Antibodies (HAMA).

研究者

发起方
genae associates

相似试验